Revenues (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Revenues	$ 240,031,000	$ 263,701,000
Contract with customer, asset and liability
Deferred revenue	$ 0	0
Remaining performance obligations	true
Contract assets	$ 0
Cost to obtain or fulfill contracts	0
Product Revenue
Disaggregation of Revenue [Line Items]
Revenues	235,472,000	261,398,000
Venlafaxine ER/VERT
Disaggregation of Revenue [Line Items]
Revenues	75,601,000	66,039,000
Methylphenidate ER
Disaggregation of Revenue [Line Items]
Revenues	73,205,000	129,469,000
Lorzone
Disaggregation of Revenue [Line Items]
Revenues	15,004,000	17,172,000
Divigel
Disaggregation of Revenue [Line Items]
Revenues	26,794,000	23,314,000
OB Complete
Disaggregation of Revenue [Line Items]
Revenues	9,851,000	10,510,000
Other
Disaggregation of Revenue [Line Items]
Revenues	35,017,000	14,894,000
Royalty Revenue
Disaggregation of Revenue [Line Items]
Revenues	3,641,000	1,959,000
License and contract revenue
Disaggregation of Revenue [Line Items]
Revenues	$ 918,000	$ 344,000
Minimum
Disaggregation of Revenue [Line Items]
Invoice payment due period	30 days
Minimum | Product Revenue
Disaggregation of Revenue [Line Items]
Invoice payment due period	30 days
Maximum
Disaggregation of Revenue [Line Items]
Invoice payment due period	60 days
Maximum | Product Revenue
Disaggregation of Revenue [Line Items]
Invoice payment due period	60 days